HeartBeam, Inc. BEAT PHARMA
Company Overview
HeartBeam, Inc. operates as a medical technology company that focuses on developing and commercializing electrocardiogram solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility. The company develops HeartBeam System, a cable-free and ambulatory 12L ECG that captures the heart's electrical signals from three dimensions for high-fidelity data collection and advanced diagnostics for arrhythmia assessment which consists of credit card sized 3D ECG recording device, a patient application, a physician portal, and powerful cloud-based algorithms. HeartBeam, Inc. was incorporated in 2015 and is based in Santa Clara, California.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -62.89% |
| 6 Months: | -69.91% |
| 3 Months: | -45.02% |
| 1 Month: | -15.02% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)38.74 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 87.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BEAT HeartBeam, Inc. PHARMA | 0.45 | -0.88 | $25.36M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -272.00K | -163.00K | -337.00K | -446.00K | -2.15M | -3.54M | -3.61M | -4.16M | -3.31M | -3.74M | -4.78M | -5.09M | -5.07M | -5.50M | -5.04M | -5.29M | -4.72M |
| Net Income | -335.00K | -210.00K | -945.00K | -1.19M | -2.15M | -3.52M | -3.58M | -4.14M | -3.15M | -3.47M | -4.61M | -4.96M | -4.98M | -5.48M | -4.97M | -5.25M | -4.70M |
| Diluted EPS | -0.09 | -0.06 | -0.26 | -0.32 | -0.27 | -0.43 | -0.44 | -0.50 | -0.16 | -0.13 | -0.17 | -0.19 | -0.19 | -0.18 | -0.15 | -0.15 | -0.12 |
| R&D Expense | 57.00K | 29.00K | 25.00K | 105.00K | 734.00K | 1.74M | 1.56M | 1.68M | 1.48M | 1.62M | 2.43M | 2.84M | 2.89M | 3.49M | 3.33M | 3.28M | 2.37M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -788.00K | -2.29M | -13.03M | -15.31M | -19.89M | -21.14M |
| Net Income | -1.07M | -4.43M | -12.96M | -14.64M | -19.45M | -21.02M |
| Diluted EPS | -0.29 | -1.03 | -1.59 | -0.72 | -0.73 | -0.62 |
| R&D Expense | 133.00K | 255.00K | 5.68M | 6.80M | 11.05M | 13.45M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 51.00K | 14.00M | 4.04M | 17.13M | 3.28M | 5.84M |
| Total Equity | -3.73M | -4.79M | 13.41M | 2.37M | 15.94M | 1.65M | 2.60M |
| Cash & Equivalents | - | - | 13.19M | 3.59M | 16.19M | 2.38M | 4.38M |
| Total Liabilities | - | 4.84M | 588.00K | 1.67M | 1.19M | 1.62M | 3.24M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -600.00K | -3.23M | -9.95M | -12.09M | -14.47M | -13.99M |
| Investing Cash Flow | - | - | 0 | -256.00K | -201.00K | -600.00K |
| Financing Cash Flow | 619.00K | 16.40M | 350.00K | 24.99M | 866.00K | 16.59M |
| Capital Expenditure | - | - | -0 | -256.00K | -201.00K | -600.00K |
| Free Cash Flow | - | - | -9.95M | -12.35M | -14.67M | -14.59M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 22.3% | -33.0% | -546.0% | -91.9% | -1,175.8% | -807.3% |
| ROCE % | - | - | - | - | - | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 3.79% | 2.14M | $861.20K |
| 2 | Blackrock Inc. | 1.75% | 987.84K | $398.00K |
| 3 | Corsair Capital Management, L.P. | 1.62% | 912.50K | $367.65K |
| 4 | Bleichroeder LP | 1.11% | 625.00K | $251.81K |
| 5 | Geode Capital Management, LLC | 0.85% | 479.39K | $193.14K |
| 6 | Smith Salley Wealth Management | 0.65% | 367.65K | $148.12K |
| 7 | UBS Group AG | 0.53% | 298.92K | $120.43K |
| 8 | Vanguard Fiduciary Trust Co | 0.49% | 274.82K | $110.72K |
| 9 | Sigma Planning Corp | 0.44% | 247.70K | $99.80K |
| 10 | Beacon Pointe Advisors, LLC | 0.44% | 247.06K | $99.54K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BEAT
Casey’s Earnings Beat Estimates. Why the Stock Is Falling. - Barron's
<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxPcmwyelV6QzBYNTlnUWw5T2NwQW5GUVRsSUpDY1BhbnNNZzNjOHQzblpzdVNRQ3hPU3llNDFOeEJ5UV9Md1psSTJXSzBrLVVGazF6Z2hLWHcxMUR4U3djWlJyazE5ZEljMWdCcEJJWWFma3d6cVZSU0J2M2w1VUhrOTY3Yw?oc=5" targe…
3 of the Best Growth Stocks to Buy for Less Than $100 Right Now - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxObTFiZVFjWk13SzE2TFVVSHJ3WDNBQ3hucjJXRGtkOHFDSTVTNVowMkFSNGJ6SmJDaUhLQTRDR0NyTnA2Qm9pdzJvX3BlZXdSRmxPN2pjcmJLWm9DSktrTTQ2b19HY3F6anpOZ0FEXzMwTzhLUlZFaU55MEVwZHVTYVQ2X3dPVjI3UzRTNk…
Up 109% in a Year, the Best AI Trade Isn’t a Chip Stock at All - 24/7 Wall St.
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxPUWhwdDVoNzhfd2FoczQtNkdhTk5JcGlUeHlEZDl4aWVMRnBVUVpCOWpfdm5UQTF1T0ZlWnprNHdyZTlXOEFBY3RUN0JKd2ZuejIydkRQZkpRbDRQMzlqV3czei1BSUtWTmYzZWQ5VGhTWUZJS3BxZGhKVVFaQThOenNrSWpqWDJwTGVjYU…
Earnings Beat Could Be A Game Changer For Veeva Stock (VEEV) - simplywall.st
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxNUHhrSFVRd2I2b2E5SzJUam5PQXpYaTktVGhXaUh4MWJUU1ZvWkpYWko5ajlZSDRkTjQ3bWVwRWpNcC1xOEt5S1BTcjJBTmZvd0o5TzVrZ1FwSHVPRnRLa0JocTdmYUhTSEZ2NC0tdnktSWpCSWtpV0pFOTJYbmdpdzNlWkQ2VEp3OElYSX…
SMCI stock climbs 4% on margin beat, though guidance signals pullback ahead - eciks.org
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE9aUU1FOEg5dHNsTDF0VzlfS1lvcXhtUVVIdU1oWW8xeUxTbmdkNjdySzYzWTcxYnpHcDB1bFNCTC1PVHVKX1k5UWdSN2ZibmhHX2JJRmZuVXo3NXc0alpTdFpkVGh3Zw?oc=5" target="_blank">SMCI stock climbs 4% on margi…
9 Stocks To Buy For September 2026 - Forbes
<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxOd3BXX2c5LWp3Yk9zb0YyV1B1Z1Btc0hHQlVSeHZvOThGTUhlUExUVTlQRkNkQWhqZUV1d0pJSHBIUWQyd1AwYjNXYWNiZW5SaWVGQ2xXV3JkaHNYTy1wb1hOaEh4X3dQSVVDZEJpVUZWX2VaMjJFRHNNNUtPWTZldHBJMktyYi1peDNMR0…
BEAT — Frequently Asked Questions
What is the current share price of HeartBeam, Inc. (BEAT)?
As of 2026-09-19 21:16 PDT, HeartBeam, Inc. (BEAT) trades at $0.45 on NasdaqCM. Its 52-week range is $0.42 to $3.44.
What is the market capitalisation of BEAT?
HeartBeam, Inc. (BEAT) has a market capitalisation of $25.36M on NasdaqCM.
What is the P/E ratio of BEAT?
BEAT trades at a trailing price-to-earnings (P/E) ratio of -0.88. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.89.
Is BEAT a good stock to buy?
This page provides a data-driven analysis of HeartBeam, Inc. (BEAT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.